SCHEMBL13020010

SCHEMBL13020010

CCn1nc(Oc2cccc(Cl)c2)c2c(N)ncnc21

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIK3CD O00329 2/20 0.49
▸ PRKDC P78527 2/20 0.49
▸ EGFR P00533 4/20 0.46
▸ CSNK1A1 P48729 1/20 0.46
▸ CSNK1D P48730 1/20 0.46
▸ CSNK1E P49674 1/20 0.46
▸ SRC P12931 8/20 0.44
▸ MAP4K4 O95819 1/20 0.44
▸ KDR P35968 4/20 0.44
▸ RET P07949 2/20 0.44
▸ ABL1 P00519 4/20 0.43
▸ HCK P08631 1/20 0.43
▸ PIK3CA P42336 1/20 0.43
▸ PIK3CB P42338 1/20 0.43
▸ MTOR P42345 1/20 0.43
▸ PIK3CG P48736 1/20 0.43
▸ EPHB4 P54760 1/20 0.43
▸ PI4KB Q9UBF8 1/20 0.43
▸ LCK P06239 1/20 0.41
▸ BTK Q06187 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13020015 0.86 CSNK1A1 (0.43) EGFRCSNK1A1CSNK1DCSNK1ESRC
SCHEMBL13064034 0.86 PIK3CD (0.55) PIK3CDPRKDCEGFRSRCKDR
SCHEMBL13020039 0.85 SRC (0.55) PIK3CDPRKDCEGFRCSNK1A1CSNK1D
SCHEMBL19359151 0.85 BTK (0.47) PIK3CDPRKDCEGFRCSNK1A1CSNK1D
SCHEMBL13020003 0.83 SRC (0.54) PIK3CDPRKDCEGFRCSNK1A1CSNK1D
SCHEMBL19359186 0.82 SRC (0.53) PIK3CDPRKDCEGFRCSNK1A1CSNK1D
SCHEMBL19359139 0.82 KCNH2 (0.54) PIK3CDPRKDCCSNK1A1CSNK1DCSNK1E
SCHEMBL3788091 0.82 SRC (0.60) PIK3CDPRKDCEGFRCSNK1A1CSNK1D
SCHEMBL19361349 0.82 ABL1 (0.59) PIK3CDPRKDCEGFRSRCKDR
SCHEMBL24005972 0.81 BTK (0.44) PIK3CDPRKDCEGFRCSNK1A1CSNK1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100331297-A1 MODULATION OF PROTEIN TRAFFICKING FOLDRX PHARMACEUTICALS, INC. (US) 2010-12-30 — — US disclosed
US-20100331297-A1 MODULATION OF PROTEIN TRAFFICKING FOLDRX PHARMACEUTICALS, INC. (US) 2010-12-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331297-A1 MODULATION OF PROTEIN TRAFFICKING RAB1A, COPB1, GOLT1B PIK3CD 2217/4885PRKDC 1498/4885EGFR 3921/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback